Stock ONCOZ ONCOZENGE AB
Add to a list
To use this feature you must be a member
Log inSign up

News OncoZenge AB

Equities

ONCOZ

SE0015504097

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:40 10/05/2024 BST 		5-day change 1st Jan Change
3.955 SEK +2.20% Intraday chart for OncoZenge AB +2.99% +27.99%
04-08 Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board CI
04-04 OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OncoZenge Appoints Anna Asplind as Phase 3 Program Manager
AQ
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs
AQ
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager
AQ
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board
AQ
Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board
CI
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™
AQ
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge
CI
Oncozenge Explores Strategic Options for Bupizeng in China
CI
OncoZenge Explores Strategic Options for BupiZenge™ in China
AQ
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge
MT
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™
AQ
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge
CI
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe
MT
OncoZenge submits application for PRIME status in the EU
AQ
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel
AQ
Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel
CI
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast
AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States
AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCOZ Stock
  4. News OncoZenge AB